INCYTE CORPORATION
At today's price, INCYTE CORPORATION (INCY) is priced for +3.2% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Incyte is a profitable biopharma built on Jakafi, its blood-cancer drug, which alone generated about $3.09 billion in 2025, with a second franchise in the skin cream Opzelura and a growing hematology-oncology portfolio behind it [Source: Incyte FY2025 results, 8-K]. • The defining risk is concentration meeting a clock: Jakafi loses patent protection in 2028, and the entire investment case turns on whether new products replace that revenue before generics arrive. • Watch the launch cadence; man
Is INCY overvalued? See what's priced in →
786 institutional managers reported holding INCY in 13F filings for the quarter ended 2026-03-31. 90 opened new positions that quarter. Held by Vanguard Group, BlackRock, Dodge & Cox, among others. On the short side, 10.6M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (4.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
INCY has cut its share count 9.4% over the past five years, spending $2.00B on repurchases. It pays no dividend. Cash returned over the past three years: $2.00B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at INCY over the trailing three years. Absence is a fact about the company, not a signal. 32 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
INCY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | +3.1% | -11.4% |
| 2023-11-01 | +4.2% | +20.5% |
| 2024-02-14 | +0.1% | -8.9% |
| 2024-05-01 | +0.7% | +8.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
INCY's latest 8-K filings: 2026-07-06 (items 8.01, 9.01); 2026-06-22 (items 8.01); 2026-06-09 (items 5.07); 2026-06-08 (items 8.01); 2026-04-28 (items 2.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.